Effects of Intravitreal Injection of Bevacizumab in Combination With Verteporfin Photodynamic Therapy
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Age Related Macular Degeneration
- Sponsor
- Asociación para Evitar la Ceguera en México
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Visual acuity improvement at 6 months
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.
Detailed Description
The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined. The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD 4 days after photodynamic therapy with verteporfin
Investigators
Eligibility Criteria
Inclusion Criteria
- •55 years old neovascular Age related acular degeneration subfoveolar neovascular membrane best corrected visual acuity better than 20/200 snellen (1.0 logMAR)
Exclusion Criteria
- •Previously treated eyes glaucoma diabetes mellitus uncontrolled hypertension coronary artery disease
Outcomes
Primary Outcomes
Visual acuity improvement at 6 months
Time Frame: undefined
undefined
Secondary Outcomes
- Retinal thickness improvement at 6 months(undefined)